One year after receiving its first conditional approval for its experimental depression medicine, Cymbalta, Eli Lilly said it received a second notice from the FDA on Wednesday saying the company does not need to conduct more clinical trials to get approval. However, Lilly still must resolve issues with its plant where Cymbalta is made.

Related Summaries